Dianthus Therapeutics (Nasdaq: DNTH) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City.
CEO Marino Garcia will join an analyst-led fireside chat on Thursday, February 12, 2026 at 10:00 am EST and hold one-on-one investor meetings. A webcast will be available under "News and Events" in the Investors section of the Dianthus Therapeutics website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – DNTH
-3.22%
-3.22%Session close to close
In the Feb 5 session, DNTH declined 3.22%, reflecting a moderate negative market reaction.
This announcement centers on Dianthus’s participation in the Guggenheim Emerging Outlook: Biotech Su...
Analysis
This announcement centers on Dianthus’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, offering a fireside chat and one-on-one investor meetings rather than new clinical or financial data. In the background, the company recently filed an effective S-3 for up to $600,000,000 of securities and has disclosed substantial cash balances near $514–525M. Recent history shows mixed price reactions to conferences and trial updates, so investors may watch upcoming clinical readouts and financing decisions as more decisive catalysts.
Key Figures
Shelf registration size:$600,000,000Preliminary cash:$514 millionAdjusted cash:$525M+5 more
Plan to present at four November 2025 investor conferences and meetings.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent history shows 4 news events where price moved contrary to news tone and only 1 aligned reaction, indicating frequent divergences between headlines and price moves.
Recent Company History
Over the last few months, Dianthus has mixed routine investor-relations updates with more substantive clinical and financial milestones. Conference and participation notices on Nov 4, Nov 24 and Jan 5 mainly expanded investor access but often coincided with volatile trading. The Nov 5 Q3 2025 results highlighted positive clinical progress and a strengthened cash position and saw a modest gain. The Dec 23 initiation of a Phase 1 trial for LBL-047 (DNTH212) was a key pipeline step yet drew a negative next-day move, similar to today’s divergence versus a routine conference announcement.
Key Terms
clinical-stage, autoimmune diseases
2 terms
clinical-stagemedical
"Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated..."
Clinical-stage describes a drug, therapy, or company whose product is being tested in human trials but has not yet received regulatory approval. For investors, it signals that the project has moved beyond lab work into real-world testing—meaning higher potential reward if trials succeed but also clear risks from trial setbacks, costs, and regulatory delay; think of it like a prototype car on public road tests that could either prove its value or reveal problems that stop it from reaching production.
autoimmune diseasesmedical
"developing next-generation therapies to transform the treatment of severe autoimmune diseases..."
Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own cells, tissues or organs, causing chronic inflammation and damage—think of the immune system as a home security system that wrongly targets the house instead of intruders. Investors care because these illnesses create sustained demand for diagnostics, long-term treatments and specialty drugs, influence regulatory scrutiny and healthcare costs, and can shape the commercial outlook for biotech and pharmaceutical investments.
NEW YORK and WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced the Company’s participation in the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York City. Marino Garcia, CEO of Dianthus Therapeutics, will participate in an analyst-led fireside chat on Thursday, February 12, 2026 at 10:00 am EST and will host one-on-one meetings with investors.
A webcast of this presentation may be accessed under “News and Events” in the Investors section of the Dianthus Therapeutics website.
About Dianthus Therapeutics Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.
When will Dianthus Therapeutics (DNTH) present at the Guggenheim Emerging Outlook: Biotech Summit 2026?
Dianthus will present on Thursday, February 12, 2026 at 10:00 am EST. According to Dianthus Therapeutics, CEO Marino Garcia will participate in an analyst-led fireside chat at that time and also hold one-on-one investor meetings during the summit.
How can investors watch Dianthus Therapeutics (DNTH) webcast of the Guggenheim summit presentation?
Investors can access a webcast via the company's investor site under "News and Events." According to Dianthus Therapeutics, the webcast will be posted in the Investors section for live or on-demand viewing following the presentation.
Who will represent Dianthus Therapeutics (DNTH) at the Guggenheim Biotech Summit 2026?
Marino Garcia, CEO of Dianthus Therapeutics, will represent the company at the event. According to Dianthus Therapeutics, he will appear in an analyst-led fireside chat and conduct one-on-one meetings with investors during the summit.
What topics will Dianthus Therapeutics (DNTH) likely cover at the Guggenheim summit presentation?
The presentation will focus on the company's clinical-stage programs and strategy for severe autoimmune diseases. According to Dianthus Therapeutics, CEO Marino Garcia will discuss the company's development approach during the analyst-led fireside chat.
Will Dianthus Therapeutics (DNTH) hold investor meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026?
Yes. Marino Garcia will host one-on-one investor meetings during the summit. According to Dianthus Therapeutics, these meetings are scheduled alongside his analyst-led fireside chat on February 12, 2026 to engage with institutional investors.
Where is the Guggenheim Emerging Outlook: Biotech Summit 2026 taking place for Dianthus Therapeutics (DNTH)?
The summit is being held in New York City. According to Dianthus Therapeutics, the company will participate in the New York event on February 12, 2026 and make a webcast available through its Investors "News and Events" page.
